Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Pieternella J. Lugtenburg, Michael Roost Clausen et al.|The Lancet|2021Cited by 337
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation DataMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|Blood|2020Cited by 64